Taiwan Food and Drug Administration published their 2023 Annual Report. Some of the development work lead by the agency was highlighted.
Improve Drug Quality Inspection Technology:
In response to the international drug safety report of the possible presence of the derivative, N-nitroso salbutamol, in salbutamol-based asthma drugs, as nitrosamines can be mutagenic, for the sake of protecting medication quality and safety, TFDA developed the test method within the shortest time possible for respective parties’ reference and adoption.
The recommended methods for testing N-nitroso Salbutamol in the active pharmaceutical ingredient salbutamol (including their English versions) were released and made available to all parties for their reference and adoption to boost the test capacity and international publicity of our country and to facilitate the exchange of information on medicinal products internationally
Method for N-nitroso-Salbutamol can be find here (english version): https://www.fda.gov.tw/tc/includes/GetFile.ashx?mid=189&id=42598&t=s